Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35


Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.

Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, Quenneville L, Miller W, Basik M.

Breast Cancer Res Treat. 2010 Feb;120(1):47-57. doi: 10.1007/s10549-009-0364-7. Epub 2009 Mar 20.


PI3K pathway alterations in cancer: variations on a theme.

Yuan TL, Cantley LC.

Oncogene. 2008 Sep 18;27(41):5497-510. doi: 10.1038/onc.2008.245. Review.


Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.

Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W.

Clin Cancer Res. 2008 Jul 15;14(14):4564-71. doi: 10.1158/1078-0432.CCR-08-0121. Epub 2008 Jun 25.


PHLiPPing the switch on Akt and protein kinase C signaling.

Brognard J, Newton AC.

Trends Endocrinol Metab. 2008 Aug;19(6):223-30. doi: 10.1016/j.tem.2008.04.001. Epub 2008 May 27. Review.


ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Stern DF.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23. doi: 10.1007/s10911-008-9083-7. Epub 2008 May 3. Review.


Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Mar 1;68(5):1471-7. doi: 10.1158/0008-5472.CAN-07-5962.


t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism.

Belkhiri A, Dar AA, Zaika A, Kelley M, El-Rifai W.

Cancer Res. 2008 Jan 15;68(2):395-403. doi: 10.1158/0008-5472.CAN-07-1580.


A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

Cancer Cell. 2007 Oct;12(4):395-402.


Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F.

Eur J Cancer. 2007 Mar;43(4):725-35. Epub 2007 Jan 23.


Herceptin: mechanisms of action and resistance.

Nahta R, Esteva FJ.

Cancer Lett. 2006 Feb 8;232(2):123-38. Review.


PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.

Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y, Shimizu N.

Br J Cancer. 2006 Jan 30;94(2):247-52.


Monoclonal antibody therapy of cancer.

Adams GP, Weiner LM.

Nat Biotechnol. 2005 Sep;23(9):1147-57. Review.


Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas.

Belkhiri A, Zaika A, Pidkovka N, Knuutila S, Moskaluk C, El-Rifai W.

Cancer Res. 2005 Aug 1;65(15):6583-92.


PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D.

Cancer Cell. 2004 Aug;6(2):117-27.


P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ.

Cancer Res. 2004 Jun 1;64(11):3981-6. Erratum in: Cancer Res. 2008 Dec 1;68(23):10005.


The role of ErbB inhibitors in trastuzumab resistance.

Miller KD.

Oncologist. 2004;9 Suppl 3:16-9. Review.


High frequency of mutations of the PIK3CA gene in human cancers.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2004 Apr 23;304(5670):554. Epub 2004 Mar 11. No abstract available.

Supplemental Content

Support Center